When was Volition founded?

Volition was founded in 1995 and raised its 1st funding round 17 years after it was founded.

Where is Volition located?

Volition is headquartered in Gembloux, Belgium.

How many employees does Volition have?

As of Oct 31, 2026, the latest employee count at Volition is 75.

Is Volition a funded company?

Volition is a funded company, having raised an undisclosed amount across 13 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jul 25, 2012.

When was the latest funding round of Volition?

Volition's latest funding was a $***** Post IPO round on Mar 31, 2026, with participation from 2 investors. Its primary sector is Oncology. Globally, the Oncology sector has seen $10.6B in funding in 2026 to date.

What is the annual revenue of Volition?

Annual revenue of Volition is between $1M and $10M as on Dec 31, 2025

Where does Volition rank among its competitors?

Volition ranks 10th amongst 393 active competitors, of which 122 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Volition?

Volition's top competitors include Guardant Health, GRAIL and BillionToOne. Among them, GRAIL secured the most recent funding round in June, 2026.

Volition - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of cancer diagnostic tests. The Nu-Q is used for early cancer diagnostics by detecting nucleosome markers of cancer and early-stage cells in the blood. It has also developed vet cancer screening tests.

Website: volition.com
Social
Email ID: *****@volition.com

Key Metrics

Founded Year

1995

Location

Gembloux, Belgium

Stage

Public

Latest Funding Round

Post IPO, Mar 31, 2026, $*****

Investors

Namur Invest & 2 more

Ranked

10^th among 393 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

75 as on Oct 31, 2026

Investment & Acquisitions

Octamer

Similar Companies

Guardant Health & 335 more

Exit Details

Public

View Volition's full profile

Volition is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
VOLITIONRX LIMITED CIN: 32075300049 , United States, Active	Oct 09, 2020	-	-	-
VOLITIONRX LTD CIN: 93314 , United States, Active	Sep 23, 1998	$1M - $10M (As on Dec 31, 2025)	-	-
VOLITION GROUP LTD CIN: 10715198 , United Kingdom, Active	Apr 06, 2017	£0 - £1M (As on Apr 30, 2025)	1 (As on Apr 30, 2019)

Volition got listed on Oct 11, 2011.

Click here to take a look at Volition's IPO in detail

Volition has raised funding over 13 rounds. Its first funding round was on Jul 25, 2012. Its latest funding round was a Post IPO round on Mar 31, 2026 for $*****. 2 investors participated in its latest round. Volition has 3 institutional investors.

Here is the list of recent funding rounds of Volition:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 31, 2026	4633009	Post IPO	7565129	3695332	6483133	5500639
May 20, 2025	3694261	Post IPO	3921681	7678434	1573681	1276922
Mar 12, 2024	6357908	Post IPO	5719660	7466485	2004078	7878107

Access funding benchmarks and valuations. Sign up today!

View details of Volition's funding rounds and investors

Volition's employee count trend

Volition has 75 employees as of Oct 26. Here is Volition's employee count trend over the years:

Uncover Volition's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Volition include Guardant Health, GRAIL and BillionToOne. Here is the list of Top 10 competitors of Volition, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	80/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	79/100
3rd	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	71/100
4th	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	69/100
5th	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	69/100
6th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	67/100
7th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 12 others	65/100
8th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	62/100
9th	Scipher Medicine 2014, Waltham (United States), Series D	Provider of precision medicine based on liquid biopsy test	$233M	Northpond Ventures, Cowen & 14 others	61/100
10th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100